Skip to main content

Quark Publishes Data Linking Proprietary Target to Pulmonary Injury, Emphysema

Premium

Quark Pharmaceuticals announced today the publication of data showing that one of its proprietary gene targets, RTP801, plays a role in cigarette smoke-induced pulmonary injury and emphysema.

In a paper published in Nature Medicine, researchers reported "increased levels of RTP801 mRNA and protein in the lungs of humans suffering from emphysema and in the lungs of mice exposed to cigarette smoke," Quark said. "Unlike normal mice, mice that could not express RTP801 did not develop emphysema following six months of intensive exposure to cigarette smoke."

"The findings … broaden the therapeutic potential of targeting RTP801," Quark CSO Elena Feinstein said in a statement.

Noting that a Quark-developed siRNA targeting RTP801 is currently in phase II development for wet age-related macular degeneration and diabetic macular edema by partner Pfizer (RNAi News 9/28/2006), she added that the new data provide "support for additional clinical applications of this drug, such as treatment of acute and chronic lung injury."

Researchers from Harvard University, Johns Hopkins University, the University of Colorado, the Bloomberg School of Public Health, National Jewish Health, the University of Pittsburgh, and Indiana University also contributed to the paper.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.